HealthDay News — Cryotherapy may be useful for preventing symptoms of chemotherapy-induced peripheral neuropathy (CIPN), according to a study published online in the Journal of the National Cancer Institute.
Akiko Hanai, OTR, from Kyoto University in Japan, and colleagues evaluated the efficacy of cryotherapy for CIPN prevention among 36 breast cancer patients treated weekly with paclitaxel (80mg/m2 for 1 hour). Study participants wore frozen gloves and socks on the dominant side for 90 minutes, including the entire duration of drug infusion.
The incidence of objective and subjective CIPN signs was lower on the intervention side versus the control side.
This held true for hand tactile sensitivity (odds ratio [OR] 20; 95% CI, 3.2 to 828.96; P <.001), foot tactile sensitivity (OR, infinite; 95% CI, 3.32 to infinite; P <.001), hand warm sense (OR, 9; 95% CI, 1.25 to 394.48; P =.02), foot warm sense (OR, 5; 95% CI, 1.07 to 46.93; P =.04), hand Patient Neuropathy Questionnaire (PNQ; OR, infinite; 95% CI, 3.32 to infinite; P <.001), and foot PNQ (OR, infinite; 95% CI, 2.78 to infinite; P <.001).
“Cryotherapy is useful for preventing both the objective and subjective symptoms of CIPN and resultant dysfunction,” conclude the authors.
Hanai A, Ishiguro H, Sozu T, et al. Effects of cryotherapy on objective and subjective symptoms of paclitaxel-induced neuropathy: prospective self-controlled trial [published October 12, 2017]. JNCI. doi: https://doi.org/10.1093/jnci/djx178